CRYOPORT, INC. Debt Securities Available For Sale Excluding Accrued Interest
CRYOPORT, INC. (CYRX) had Debt Securities Available For Sale Excluding Accrued Interest of $28.71 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest · last filed 2026-08-06
- 2026-06-30: Debt Securities Available For Sale Excluding Accrued Interest $28.71M.
- 2026-03-31: Debt Securities Available For Sale Excluding Accrued Interest $32.60M.
- 2025-12-31: Debt Securities Available For Sale Excluding Accrued Interest $61.53M.
- 2025-09-30: Debt Securities Available For Sale Excluding Accrued Interest $66.17M.
| Period end | Debt Securities Available For Sale Excluding Accrued Interest | Debt Securities Available For Sale Excluding Accrued Interest as first filed |
|---|---|---|
| 2026-06-30 | $28.71M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $32.60M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $61.53M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $66.17M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $84.27M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $109.60M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $118.78M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $127.98M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $280.63M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $298.47M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $309.32M 10-K · filed 2025-03-07 | |
| 2023-09-30 | $308.87M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $337.48M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $382.79M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $386.95M 10-K · filed 2024-03-13 | |
| 2022-09-30 | $400.05M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $411.07M 10-Q · filed 2022-08-04 | |
| 2021-12-31 | $379.69M 10-K · filed 2023-02-28 | $379.69K 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |